Thus, low systemic plasma IP-10 levels in some patients could reflect low disease activity already at baseline, or compartmentalized production and degradation of cytokines at the site of infection, both limiting the use of the assay in this group of TB patients. This evidence concerns the gene CXCL10 and infection.